INmune Bio, Inc. (INMB)
2.36
+0.12
(+5.36%)
USD |
NASDAQ |
Sep 02, 16:00
2.36
0.00 (0.00%)
After-Hours: 20:00
INmune Bio Net Income (Quarterly) : -1.273M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.273M |
| March 31, 2026 | -5.407M |
| December 31, 2025 | -5.264M |
| September 30, 2025 | -6.472M |
| June 30, 2025 | -24.46M |
| March 31, 2025 | -9.739M |
| December 31, 2024 | -9.218M |
| September 30, 2024 | -12.09M |
| June 30, 2024 | -9.746M |
| March 31, 2024 | -11.02M |
| December 31, 2023 | -8.408M |
| September 30, 2023 | -8.563M |
| June 30, 2023 | -6.501M |
| March 31, 2023 | -6.536M |
| December 31, 2022 | -5.833M |
| September 30, 2022 | -7.725M |
| June 30, 2022 | -6.838M |
| March 31, 2022 | -6.903M |
| December 31, 2021 | -9.671M |
| September 30, 2021 | -9.458M |
| Date | Value |
|---|---|
| June 30, 2021 | -6.655M |
| March 31, 2021 | -4.556M |
| December 31, 2020 | -3.204M |
| September 30, 2020 | -4.717M |
| June 30, 2020 | -2.108M |
| March 31, 2020 | -2.070M |
| December 31, 2019 | -2.318M |
| September 30, 2019 | -3.067M |
| June 30, 2019 | -0.3921M |
| March 31, 2019 | -1.901M |
| December 31, 2018 | -1.880M |
| September 30, 2018 | -1.540M |
| June 30, 2018 | -6.174M |
| March 31, 2018 | -2.846M |
| December 31, 2017 | -0.4282M |
| September 30, 2017 | -0.3075M |
| June 30, 2017 | -0.1651M |
| March 31, 2017 | 0.0306M |
| December 31, 2016 | -0.1347M |
| September 30, 2016 | -0.0542M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.536M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.273M |
| EPS Diluted (Quarterly) | -0.0476 |
| Enterprise Value | 44.94M |
| Earnings Yield | -29.34% |
| Normalized Earnings Yield | -30.01 |